Distinguished in Chronic Myelomonocytic Leukemia (CMML)

Raphael A. Itzykson

Paris, FR 
Distinguished in Chronic Myelomonocytic Leukemia (CMML)
Paris, FR 
OverviewLocationsClinical Research

Overview

Raphael Itzykson practices in Paris, France. Mr. Itzykson is rated as a Distinguished expert by MediFind in the treatment of Chronic Myelomonocytic Leukemia (CMML). His top areas of expertise are Chronic Myelomonocytic Leukemia (CMML), Leukemia, Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

His clinical research consists of co-authoring 158 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 37 articles and participated in 1 clinical trial in the study of Chronic Myelomonocytic Leukemia (CMML).

Gender
Male

Locations

Paris, France
Other Locations
Bobigny, France
Villejuif, France
Port-saint-louis-du-rhone, France
Orsay, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CPI-613, Cytarabine, Mitoxantrone, Etoposide, Fludarabine, Filgrastim
Study Phase: Phase 3
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: April 28, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II Study of Eltrombopag in Patients With Chronic Myelomonocytic Leukemia and Thrombocytopenia
A Phase I/II Study of Eltrombopag in Patients With Chronic Myelomonocytic Leukemia and Thrombocytopenia
Enrollment Status: Completed
Publish Date: April 20, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

158 Total Publications

Ovarian tissue autotransplantation in acute leukemia: balancing the risk of relapse and the hope of parenthood.
Ovarian tissue autotransplantation in acute leukemia: balancing the risk of relapse and the hope of parenthood.
Journal: Haematologica
Published: March 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Itzykson's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile